下咽癌共病食管癌的高危因素及预后分析

doi:10.6040/j.issn.1673-3770.0.2018.234

摘要/Abstract

摘要： 目的探讨下咽癌共病同时性食管癌的高危因素及预后。方法 2011年1月至2014年3月诊治的200例下咽癌患者作为研究对象,回顾性分析患者的一般资料、肿瘤信息和随访情况。先对可能影响下咽癌共病同时性食管癌的危险因素进行单因素分析,组间比较采用卡方检验,进一步将有统计学差异的因素纳入Logistic回归分析。生存率的分析采用Kaplan-Meier法。结果单因素分析发现,年龄(<55岁)、男性、重度吸烟史、重度饮酒史和肿瘤侵犯部位≥3个是下咽癌患者共病同时性食管癌的高危因素(P<0.05)。多因素分析结果显示,年龄(<55岁)、重度吸烟史、重度饮酒史和肿瘤侵犯部位≥3个是下咽癌患者共病同时性食管癌的独立危险因素(P<0.05)。200例下咽癌患者中位生存时间仅为37.5个月,5年生存率仅为36.7%。56例下咽癌共病同时性食管癌患者中位生存时间为24.8个月,低于下咽癌不伴同时性食管癌患者(P<0.05)。早期食管癌(0+Ⅰ期)患者的中位生存时间为29.2个月,明显高于进展期食管癌(Ⅱ+Ⅲ期)的15.8个月,差异有统计学意义(P<0.05)。结论下咽癌共病同时性食管癌患者的生存时间较低。年龄(<55岁)、重度吸烟史、重度饮酒史和肿瘤侵犯部位≥3个是下咽癌患者共病同时性食管癌的独立危险因素,临床上应该针对这些高危因素进行早期干预。

关键词: 下咽癌, 食管癌, 预后, 危险因素

Abstract: Objective To investigate the risk factors and prognosis of hypopharyngeal carcinoma patients with esophageal cancer. Methods This study included 200 patients with esophageal cancer in our hospital from January 2011 to March 2014. General data, tumor information, and follow-up of patients were retrospectively analyzed. First, the risk factors of esophageal cancer with hypopharyngeal carcinoma were analyzed by univariate analysis with comparisons between groups using the chi square test(2). Logistic regression analysis was then performed for factors with statistical differences. The Kaplan-Meier method was used to analyze the survival rate. Results Single-factor analysis revealed that age(<55 years), male gender, severe smoking history, severe alcohol consumption history, and >3 tumor invasion sites were high risk factors for comorbidity of esophageal cancer in hypopharyngeal cancer patients(P<0.05). The results of the multifactor analysis showed that age(<55 years), severe smoking history, severe alcohol consumption history, and >3 tumor invasion sites were independent risk factors for comorbidity of hypopharyngeal carcinoma(P<0.05). The median survival time of the 200 hypopharyngeal cancer patients was 37.5 months, and the 5-year survival rate was 36.7%. The median survival time of 56 patients with concurrent hypopharyngeal carcinoma and concurrent esophageal cancer was 24.8 months, which was significantly lower than that in patients with hypopharyngeal carcinoma without concurrent esophageal cancer(P<0.05). The median survival time in patients with early-stage esophageal carcinoma(0+Ⅰ stage)was 29.2 months, which was significantly higher than that in patients with advanced esophageal carcinoma(Ⅱ+Ⅲ stage), and the difference was statistically significant(P<0.05). Conclusion The survival time in hypopharyngeal cancer patients with concurrent esophageal cancer is relatively low. Age(<55 years), severe smoking history, severe alcohol consumption history, and >3 tumor invasion sites are independent risk factors for comorbidity of hypopharyngeal cancer, and early interventions should be implemented in clinical practice.

Key words: Hypopharyngeal carcinoma, Esophageal cancer, Prognosis, Risk factors

中图分类号:

R739.6

黄河,欧阳晖. 下咽癌共病食管癌的高危因素及预后分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 82-86.

HUANG He, OUYANG Hui. Risk factors and prognosis of esophageal cancer with hypopharyngeal carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 82-86.

参考文献 19

[1]	Rodrigo JP, Grilli G, Shah JP, et al. Selective neck dissection in surgically treated head and neck squamous cell carcinoma patients with a clinically positive neck: Systematic review[J]. Eur J Surg Oncol, 2018, 44(4): 395-403. doi:10.1016/j.ejso.2018.01.003.
[2]	Osumi H, Yoshio T, Chin K, et al. Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer[J]. Gastric Cancer, 2016, 19(2): 625-630. doi:10.1007/s10120-015-0517-9.
[3]	Lee KD, Lu CH, Chen PT, et al. The incidence and risk of developing a second primary esophageal cancer in patients with oral and pharyngeal carcinoma: a population-based study in Taiwan over a 25 year period[J]. BMC Cancer, 2009, 9: 373. doi:10.1186/1471-2407-9-373.
[4]	Muto M, Nakane M, Katada C, et al. Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites[J]. Cancer, 2004, 101(6): 1375-1381. doi:10.1002/cncr.20482.
[5]	Zhang QL, Zhao LG, Li HL, et al.The joint effects of major lifestyle factors on colorectal cancer risk among Chinese men: A prospective cohort study[J]. Int J Cancer,2018,142(6):1093-1101. doi: 10.1002/ijc.31126.
[6]	黄根牙,马兴刚,王昌成. 重度饮酒与HBV相关肝癌危险性的关系[J]. 中华肿瘤防治杂志, 2005, 12(6): 405-408. doi:10.3969/j.issn.1673-5269.2005.06.002. HUANG Genya,MA Xinggang,WANG Changcheng. Heavy alcohol consumption can enhance risk of hepatocellular carcinoma associated with hepatitis B virus infection[J]. Chinese Journal of Cancer Prevention and Treatment, 2005, 12(6): 405-408. doi:10.3969/j.issn.1673-5269.2005.06.002.
[7]	徐伟,吕正华,杨哲,等. 149例下咽癌手术及术后放射治疗的预后分析[J]. 中华耳鼻咽喉头颈外科杂志, 2014, 49(7): 533-538. doi:10.3760/cma.j.issn.1673-0860.2014.07.002. XU Wei, LÜ Zhenghua, YANG Zhe, et al. Prognostic factors affecting results of comprehensive treatment of hypopharyngeal carcinoma[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery[J] , 2014, 49(7): 533-538. doi:10.3760/cma.j.issn.1673-0860.2014.07.002.
[8]	Chen XM, Wang JF, Wang R, et al. Th1-, Th2-, and Th17-associated cytokine expression in hypopharyngeal carcinoma and clinical significance[J]. Eur Arch Otorhinolaryngol, 2016, 273(2): 431-438. doi:10.1007/s00405-015-3779-2.
[9]	白文文,宋玉芝,刘明,等. SIB-IMRT技术在颈及胸上段食管癌中的临床应用[J]. 中华肿瘤防治杂志, 2016, 23(4): 248-252. doi:10.16073/j.cnki.cjcpt.2016.04.010. BAI Wenwen, SONG Yuzhi, LIU Ming, et al. Clinical application of simultaneous integrated boost intensity-modulated radiation therapy in cervical and upper esophageal carcinoma[J].Chinese Journal of Cancer Prevention and Treatment, 2016, 23(4): 248-252. doi:10.16073/j.cnki.cjcpt.2016.04.010.
[10]	郑浩,汪灏,唐汉,等. 新辅助同步放化疗与新辅助化疗治疗局部进展期食管鳞癌的疗效分析[J]. 中华消化外科杂志, 2017, 16(5): 464-468. doi:10.3760/cma.j.issn.1673-9752.2017.05.006. ZHENG Hao, WANG Hao, TANG Han, et al. Effect analysis of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in the treatment of locally advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Digestive Surgery, 2017, 16(5): 464-468. doi:10.3760/cma.j.issn.1673-9752.2017.05.006.
[11]	Li B, Xu WW, Han L, et al. MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF[J]. Oncogene, 2017, 36(28): 3986-4000. doi:10.1038/onc.2017.29.
[12]	Deng XF, Liu QX, Hou B, et al. Esophageal cancer with a synchronous multiple carcinoid of the duodenal bulb[J]. Indian J Surg, 2015, 77(6): 543-544. doi:10.1007/s12262-015-1338-0.
[13]	Lo OS, Law S, Wei WI, et al. Esophageal cancers with synchronous or antecedent head and neck cancers: a more formidable challenge?[J]. Ann Surg Oncol, 2008, 15(6): 1750-1756. doi:10.1245/s10434-008-9860-y.
[14]	Lee DH, Roh JL, Baek S, et al. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma[J]. Otolaryngol Head Neck Surg, 2013, 149(4): 579-586. doi:10.1177/0194599813496373.
[15]	李思涵,陈智琴,李光. 30例头颈部鳞癌合并同时性食管癌患者疗后临床分析[J]. 中华放射肿瘤学杂志, 2017, 26(7): 728-731. doi:10.3760/cma.j.issn.1004-4221.2017.07.002. LI Sihan,CHEN Zhiqin,LI Guang,et al. A clinical analysis of 30 patients with synchronous head and neck and esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(7): 728-731. doi:10.3760/cma.j.issn.1004-4221.2017.07.002.
[16]	Haguenoer JM, Cordier S, Morel C, et al. Occupational risk factors for upper respiratory tract and upper digestive tract cancers[J]. Br J Ind Med, 1990, 47(6): 380-383. doi:10.1136/oem.47.6.380.
[17]	Lim H, Kim DH, Jung HY, et al. Clinical significance of early detection of esophageal cancer in patients with head and neck cancer[J]. Gut Liver, 2015, 9(2): 159-165. doi:10.5009/gnl13401.
[18]	Katsoulakis E, Riaz N, Hu M, et al. Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institutions experience[J]. The Laryngoscope, 2016, 126(3): 620-626. doi:10.1002/lary.25509.
[19]	Visser E, Franken IA, Brosens LA, et al. Prognostic gene expression profiling in esophageal cancer: a systematic review[J]. Oncotarget, 2017, 8(3): 5566-5577. doi:10.18632/oncotarget.13328.

相关文章 15

[1]	刘佳珲,田汝宪,李玉梅,宋西成. 构建铜死亡相关lncRNA模型评估头颈鳞状细胞癌预后[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 49-64.
[2]	缪红利,张妍春,郝琳娜,唐乐,何英楠. 活动性眼弓形虫病临床特征及预后分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 82-89.
[3]	彭中华,陈竹,袁洛花,余绍兰,马玉玲. 原发性鼻腔高级别非肠型腺癌1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 95-98.
[4]	李赞,卢奇,申卫东,侯昭晖,吴南. 坏死性外耳道炎临床诊治18例[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 17-22.
[5]	刘玉柱,陈尧,苑铁君,李春森,李波. 喉纤维肉瘤1例并相关文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 133-137.
[6]	王焕霞,王淑雅,王影,孙璇,黄杰,王兴荣. 孔源性视网膜脱离玻璃体切除术后继发黄斑前膜的危险因素分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 181-185.
[7]	黄佳丽,刘梓琪,徐娟,陈曦,张立庆,周涵. 咽部梭形细胞鳞状细胞癌的临床及预后分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 94-100.
[8]	李美辰,陈海玲,李阳,马登殿. 下鼻甲黏液囊肿1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 91-94.
[9]	张琳,辛运超,尚小领,解琪,刘亚超. cN0期甲状腺微小乳头状癌颈部中央区及侧颈区淋巴结转移率、危险因素及清扫策略的临床研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 62-69.
[10]	杨开炎, 唐凤珠, 覃启才, 李旭祥, 冯大益, 农丰靖, 杨秋云. 异常纺锤体样小头畸形相关蛋白在鼻咽癌中的表达及其临床意义[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 18-25.
[11]	王凯健,陈雪生,王威. 血小板-淋巴细胞比值与喉鳞状细胞癌预后相关性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 67-73.
[12]	张佳佳,石安妮,邢御,洪玉颖,白鹏. 针刺联合西药治疗全聋型突发性聋1例与文献复习[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 88-92.
[13]	张永红,张辉,王彩华,杨欣欣,吴允刚,赵玉凤,庞太忠,李晓瑜. 基于TCGA数据库构建喉鳞状细胞癌免疫相关基因预后模型及筛选靶向分子药物[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 54-62.
[14]	刘楠,逄明杰. 鼻内镜泪囊鼻腔吻合术预后影响因素的研究进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 149-155.
[15]	吴波,黄天德,闫斌,陈伊,汤勇. 焦虑抑郁状态与特发性耳鸣预后的相关性研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 46-52.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed